ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2004
Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- RED light promotes flavonoid and phenolic accumulation in Cichorium spp. callus culture as anti-candida agent.Scientific reports · 2025Article
- Potential Original Drug for Aspergillosis: In Vitro and In Vivo Effects of 1-N,N-Dimethylamino-5-Isocyanonaphthalene (DIMICAN) onJournal of fungi (Basel, Switzerland) · 2022Article
- The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles.Pharmaceutics · 2021Review
- Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?Journal of fungi (Basel, Switzerland) · 2020Review
- Virulence and biofilms as promising targets in developing antipathogenic drugs against candidiasis.Future science OA · 2020Review
- Resistance mechanism and proteins inMycology · 2019Review
- Antifungal and Zearalenone Inhibitory Activity of Pediococcus pentosaceus Isolated from Dairy Products on Fusarium graminearum.Frontiers in microbiology · 2016Article
- Synthesis and antioxidant activity evaluation of new compounds from hydrazinecarbothioamide and 1,2,4-triazole class containing diarylsulfone and 2,4-difluorophenyl moieties.International journal of molecular sciences · 2014Article
- Phenyl aldehyde and propanoids exert multiple sites of action towards cell membrane and cell wall targeting ergosterol in Candida albicans.AMB Express · 2013Article
- Article
- Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.Antimicrobial agents and chemotherapy · 2011Article
- Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2010Article
- Efflux-mediated antifungal drug resistance.Clinical microbiology reviews · 2009Review
- Treatment of invasive candidiasis in immunocompromised pediatric patients.Paediatric drugs · 2008Review
- Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2007Article
- Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2005Review
- Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).Journal of clinical microbiology · 2005Article
- Posaconazole.Drugs · 2005Review
- Antimicrobial and antileishmanial activities of hypocrellins A and B.Antimicrobial agents and chemotherapy · 2004Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As invasive fungal infections in immunocompromised patients become increasingly important, the field of antifungal chemotherapy continues to evolve rapidly. New agents have entered the clinical arena, providing physicians with a variety of choices for treatment of most infections. Standardized methods for testing the in vitro susceptibility of fungi have become available, and concentration-effect relationships are increasingly explored. Finally, the availability of an entirely new class of antifungal agents is opening new opportunities for combination therapy of infections that are notoriously difficult to treat and carry a dismal prognosis. However, the ongoing progress in these key areas has also made antifungal chemotherapy considerably more complex and susceptible to misconceptions. Continuing efforts in the laboratory and well designed collaborative clinical trials are needed more than ever to turn opportunities into lasting benefit for patients at risk for or suffering from life-threatening invasive mycoses.
Indexed as
Identifiers
15015031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.